BNTC
Benitec Biopharma Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Benitec Biopharma Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Last report0 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No changes.
No changes.
Annual filing, covered
10-K parsed · Sep 14 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Sep 14 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Largest filed tie
—
−8.53%
vs ±33.9% implied · ×0.25
shaded = implied · ▲▼ = realized
Benitec Biopharma Inc.
9.28
+0.88 · +10.43%
post 9.28 0.00%
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Benitec Biopharma Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Benitec Biopharma Inc.'s 6 closest co-movers, none share that code.
| Manager | Value | % base | |
|---|---|---|---|
| Suvretta | $154.5M | 34.85% | 0.00% |
| Jupiter Topco | $33.1M | 7.47% | — |
| Franklin Resources | $32.3M | 7.28% | +1.46% |
| Adage Capital Partners GP | $28.4M | 6.40% | 0.00% |
| RA Capital Management | $24.8M | 5.58% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Suvretta | $154.5M | 34.85% | 0.00% |
| Jupiter Topco | $33.1M | 7.47% | — |
| Franklin Resources | $32.3M | 7.28% | +1.46% |
| Adage Capital Partners GP | $28.4M | 6.40% | 0.00% |
| RA Capital Management | $24.8M | 5.58% | 0.00% |
Bull2
Bear1
Expected move
No implied move.